VANCOUVER, Oct. 24, 2019 /PRNewswire/ - Choom™ (CSE: CHOO; OTCQB: CHOOF), an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that Sitka Weedworks (formerly Specialty Medijuana Products Inc.), of which Choom is 9.8% equity stakeholder, has received two

TORONTO, Oct. 24,  2019 /PRNewswire/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today announced it intends to release its third quarter, 2019

GAITHERSBURG, Md., Oct. 24, 2019 /PRNewswire/ -- MaxCyte, the global cell-based therapies and life sciences company, announces today that, having completed dosing of the second cohort of patients, clinical investigators have initiated dosing in the third cohort of patients of MaxCyte's Phase I clinical trial with the next higher cell dose of MCY-M11. This lead, whol

PRINCETON, N.J., Oct. 24, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (US) Patent Office has allowed the divisiona

NEW YORK, Oct. 24, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") announced today that it will a host a conference call and webcast to highlight interim results from the pivotal Phase 3 SIERRA trial for its lead program, Iomab-B. The SIERRA trial (Study of Iomab-B in Elderly Relapse

OLDWICK, N.J., Oct. 24, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the European Medicines Agency (EMA) has granted PRV-031 (teplizumab) PRIority MEdicines (PRIME) designation for the prevention or delay of clinical type 1 diabe

GUILFORD, Conn., Oct. 24, 2019 /PRNewswire/ -- Butterfly Network, Inc. announced today that it will be releasing a suite of simple and powerful enterprise tools for hospitals and healthcare systems to ease the current ultrasound pain points around documentation, quality assurance and billing. By making ultrasound workflow truly mobile, enhancing the security of Butterfly

BOSTON, Oct. 24, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that the Company's cystic fibrosis transmembrane conductance

JERUSALEM, Oct. 24, 2019 /PRNewswire/ -- Pepticom, a leader in artificial intelligence peptide drug discovery, announced today that it has secured $5 million in Series A funding from the Chartered Group. 

COSTA MESA, Calif., Oct. 24, 2019 /PRNewswire/ -- The key to winning the hearts and minds of senior living community residents and their families is ensuring the facility has a great staff that communicates clearly, knows personal details about residents and makes them feel like they are part of a community. According to the J.D. Power 2019 U.S. Senior Living Satisf